Evofem Biosciences Inc. (NASDAQ:EVFM) went up by 7.11% from its latest closing price compared to the recent 1-year high of $7.50. The company’s stock price has collected 14.80% of gains in the last five trading sessions. Press Release reported on 09/16/20 that Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference
Is It Worth Investing in Evofem Biosciences Inc. (NASDAQ :EVFM) Right Now?
Plus, the 36-month beta value for EVFM is at 0.36. Opinions of the stock are interesting as 3 analysts out of 4 who provided ratings for Evofem Biosciences Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $7.00. EVFM currently public float of 80.12M and currently shorts hold a 16.29% ratio of that float. Today, the average trading volume of EVFM was 4.61M shares.
EVFM’s Market Performance
EVFM stocks went up by 14.80% for the week, with a monthly drop of -26.01% and a quarterly performance of -18.47%, while its annual performance rate touched -50.10%. The volatility ratio for the week stands at 8.37% while the volatility levels for the past 30 days are set at 10.65% for Evofem Biosciences Inc.. The simple moving average for the period of the last 20 days is 2.22% for EVFM stocks with a simple moving average of -40.78% for the last 200 days.
Analysts’ Opinion of EVFM
Many brokerage firms have already submitted their reports for EVFM stocks, with Stifel repeating the rating for EVFM by listing it as a “Buy.” The predicted price for EVFM in the upcoming period, according to Stifel is $5 based on the research report published on October 02nd of the current year 2020.
Morgan Stanley, on the other hand, stated in their research note that they expect to see EVFM reach a price target of $3. The rating they have provided for EVFM stocks is “Equal-Weight” according to the report published on August 20th, 2020.
Piper Sandler gave a rating of “Overweight” to EVFM, setting the target price at $11 in the report published on June 08th of the current year.
EVFM Trading at -10.16% from the 50-Day Moving Average
After a stumble in the market that brought EVFM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.87% of loss for the given period.
Volatility was left at 10.65%, however, over the last 30 days, the volatility rate increased by 8.37%, as shares sank -28.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.72% lower at present.
During the last 5 trading sessions, EVFM rose by +14.80%, which changed the moving average for the period of 200-days by -55.63% in comparison to the 20-day moving average, which settled at $2.45. In addition, Evofem Biosciences Inc. saw -58.51% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EVFM starting from Barrans Russell, who purchase 3,000 shares at the price of $2.08 back on Sep 11. After this action, Barrans Russell now owns 279,052 shares of Evofem Biosciences Inc., valued at $6,240 using the latest closing price.
Barrans Russell, the Chief Commercial Officer of Evofem Biosciences Inc., purchase 1,000 shares at $2.71 during a trade that took place back on Sep 10, which means that Barrans Russell is holding 276,052 shares at $2,710 based on the most recent closing price.
Stock Fundamentals for EVFM
Equity return is now at value -359.90, with -180.40 for asset returns.
Based on Evofem Biosciences Inc. (EVFM), the company’s capital structure generated 1.26 points at debt to equity in total, while total debt to capital is 1.24.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.09.